Ji Heng Pharmaceutical announced that revenue for the first half of 2026 was 241 million yuan, a year-on-year decrease of 50.51%; net loss was 20138,500 yuan, a loss margin of 84.62% narrower than the same period last year. The net cash flow from operating activities was -669.25,500 yuan, a year-on-year decrease of 1035.96%. In addition, the total principal and interest on loans applied by the company from SPD Bank and others of 326 million yuan will not be settled, and the subsidiary has confirmed a debt of 136 million yuan for possible joint guarantee liabilities. The company held partial equity pledge loans from Liaoyuan Baikang Pharmaceutical and Chongqing Chunrui Pharmaceutical Chemical. As of June 30, the loan balances were 65.5748 million yuan and 403 million yuan respectively.

Ji Heng Pharmaceutical announced that revenue for the first half of 2026 was 241 million yuan, a year-on-year decrease of 50.51%; net loss was 20138,500 yuan, a loss margin of 84.62% narrower than the same period last year. The net cash flow from operating activities was -669.25,500 yuan, a year-on-year decrease of 1035.96%. In addition, the total principal and interest on loans applied by the company from SPD Bank and others of 326 million yuan will not be settled, and the subsidiary has confirmed a debt of 136 million yuan for possible joint guarantee liabilities. The company held partial equity pledge loans from Liaoyuan Baikang Pharmaceutical and Chongqing Chunrui Pharmaceutical Chemical. As of June 30, the loan balances were 65.5748 million yuan and 403 million yuan respectively.